Metformin temporal and localized effects on gut glucose metabolism assessed using 18F-FDG PET in mice

Journal of Nuclear Medicine

Volumn 54, Issue 2, 2013, Pages 259-266

  Massollo, Michela ^a   Marini, Cecilia ^b   Brignone, Massimo ^a   Emionite, Laura ^c   Salani, Barbara ^c   Riondato, Mattia ^a   Capitanio, Selene ^a   Fiz, Francesco ^a   Democrito, Alessia ^a   Amaro, Adriana ^d   Morbelli, Silvia ^a   Piana, Michele ^d   Maggi, Davide ^c   Cilli, Michele ^c   Pfeffer, Ulrich ^d   Sambuceti, Gianmario ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

AMPK; GI tract; Metformin; Positron emission tomography; TXNIP

Indexed keywords

ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; FLUORODEOXYGLUCOSE F 18; MESSENGER RNA; METFORMIN; PROTEIN KINASE; THIOREDOXIN INTERACTING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG UPTAKE; ENZYME PHOSPHORYLATION; EX VIVO STUDY; FEMALE; GENE; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; INTESTINE ABSORPTION; INTESTINE CELL; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; THIOREDOXIN INTERACTING PROTEIN GENE; UPREGULATION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CARRIER PROTEINS; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; GLUCOSE; HYPOGLYCEMIC AGENTS; INTESTINES; KINETICS; MALE; METFORMIN; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIOREDOXINS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84873553761     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.106666     Document Type: Article

References (30)

1. 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35:95-99.
2. Bybel B, Greenberg ID, Paterson J, Ducharme J, Leslie WD. Increased F-18 FDG intestinal uptake in diabetic patients on metformin: a matched case-control analysis. Clin Nucl Med. 2011;36:452-456.
3. Oh JR, Song HC, Chong A, et al. Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin. AJR. 2010;195:1404-1410.
4. Ozülker T, Ozülker F, Mert M, Ozpaçaci T. Clearance of the high intestinal (18) F-FDG uptake associated with metformin after stopping the drug. Eur J Nucl Med Mol Imaging. 2010;37:1011-1017.
5. Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metforminstimulated glucose utilization. Br J Pharmacol. 1994;112:671-675.
6. Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol. 2000;59: 887-890.
7. Kim S, Chung JK, Kim BT, et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET. Clin Positron Imaging. 1999;2:273-279.
8. Stahl A, Weber WA, Avril N, Schwaiger M. Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin. 2000;39:241-245.
9. Miraldi F, Vesselle H, Faulhaber PF, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med. 1998;23:3-7.
10. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167-1174.
11. Shaked M, Ketzinel-Gilad M, Cerasi E, Kaiser N, Leibowitz G. AMP-activated protein kinase (AMPK) mediates nutrient regulation of thioredoxin-interacting protein (TXNIP) in pancreatic beta-cells. PLoS ONE. 2011;6:e28804.
12. Guide for the Care and Use of Laboratory Animals. Bethesda, MD: National Institutes of Health; 1985. NIH publication 85-23.
13. Bachmanov AA, Redd DR, Beauchamp GK, Tordoff MG. Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav Genet. 2002;32:435-443.
14. Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERa negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 2009;113:101-111.
15. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-tobrain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
16. Levin SR, Pehlevanian MZ, Lavee AE, Adachi RI. Secretion of an insulinotropic factor from isolated, perfused rat intestine. Am J Physiol. 1979;236: E710-720.
17. Salani B, Maffioli S, Hamoudane M, et al. Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. FASEB J. 2012;26:788-798.
18. Wiernsperger NF. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Diabetes Metab. 1999;25:110-127.
19. Brunmair B, Staniek K, Gras F, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes. 2004;53:1052-1059.
20. Wilcock C, Bailey CJ. Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol. 1990;39:1831-1834.
21. Chen KS, DeLuca HF. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim Biophys Acta. 1994;1219:26-32.
22. Nishiyama A, Matsui M, Iwata S, et al. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem. 1999;274:21645-21650.
23. Oka S, Liu W, Masutani H, et al. Impaired fatty acid utilization in thioredoxin binding protein-2 (TBP-2)-deficient mice: a unique animal model of Reye syndrome. FASEB J. 2006;20:121-123.
24. Yu FX, Chai TF, He H, Hagen T, Luo Y. Thioredoxin-interacting protein (Txnip) gene expression: sensing oxidative phosphorylation status and glycolytic rate. J Biol Chem. 2010;285:25822-25830.
25. Chai TF, Hong SY, He H, et al. A potential mechanism of metformin-mediated regulation of glucose homeostasis: inhibition of thioredoxin-interacting protein (Txnip) gene expression. Cell Signal. 2012;24:1700-1705.
26. Iozzo P, Hallsten K, Oikonen V, et al. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care. 2003;26:2069-2074.
27. Zhang ZJ, Zhen ZJ, Kahn H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes. Diabetes Care. 2011;34: 2323-2328.
28. Mashhedi H, Blouin MJ, Zakikhani M, et al. Metformin abolishes increased tumor (18)F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet. Cell Cycle. 2011;10:2770-2778.
29. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67:6745-6752.
30. Graham ML, Janecek JL, Kittredge JA, Hering BJ, Schuurnan HJ. The streptozotocin-induced diabetic nude mouse model: differences between animals from different sources. Comp Med. 2011;61:356-360.